Comparing Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and Oncocyte (NASDAQ:IMDX)

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and Oncocyte (NASDAQ:IMDX) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership and valuation.

Insider and Institutional Ownership

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. Comparatively, 55.3% of Oncocyte shares are owned by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by insiders. Comparatively, 2.2% of Oncocyte shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Lakefront Biotherapeutics American Depositary Shares and Oncocyte”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares	$1.26 billion	1.66	$363.05 million	($1.41)	-22.45
Oncocyte	$4.05 million	22.86	-$50.22 million	($1.49)	-1.90

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Oncocyte. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Oncocyte, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Lakefront Biotherapeutics American Depositary Shares and Oncocyte’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A
Oncocyte	-2,955.63%	N/A	-107.52%

Analyst Recommendations

This is a breakdown of recent recommendations for Lakefront Biotherapeutics American Depositary Shares and Oncocyte, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakefront Biotherapeutics American Depositary Shares	0	5	3	0	2.38
Oncocyte	1	0	2	0	2.33

Lakefront Biotherapeutics American Depositary Shares presently has a consensus price target of $35.50, indicating a potential upside of 12.16%. Oncocyte has a consensus price target of $10.50, indicating a potential upside of 271.02%. Given Oncocyte’s higher probable upside, analysts clearly believe Oncocyte is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Risk and Volatility

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.24, indicating that its share price is 76% less volatile than the S&P 500. Comparatively, Oncocyte has a beta of 1.8, indicating that its share price is 80% more volatile than the S&P 500.

Summary

Lakefront Biotherapeutics American Depositary Shares beats Oncocyte on 8 of the 13 factors compared between the two stocks.

About Lakefront Biotherapeutics American Depositary Shares

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company’s pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

About Oncocyte

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.